Bristol Myers Beats Estimates, Boosts Forecast

Bristol Myers Squibb reported robust second-quarter results, prompting an upward revision of its full-year financial projections. The company achieved revenue of $12.97 billion, a 6% increase year-over-year, surpassing analyst expectations. Adjusted earnings per share also came in higher than anticipated at $2.04.

These strong results stem from significant sales of key products, including the blood thinner Eliquis, which saw a 22% increase in quarterly revenue. Newer drugs such as heart medicine Camzyos and anemia treatment Reblozyl also demonstrated impressive growth, exceeding market predictions.

In response to this performance, Bristol Myers now forecasts full-year revenue between $49 billion and $50 billion, a substantial increase from its previous guidance. The company is actively managing the decline in sales from older, generic-competing drugs like Revlimid, focusing on its growing portfolio of newer medications. The oncology immunotherapy Opdivo, while seeing a slight dip, also showed promise with its new subcutaneous version, Qvantig, which exceeded revenue expectations.